Triglycerides Articles

Articles
Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association
Kirkpatrick CF, Sikand G, Petersen KS, et al.
Journal:
J Clin Lipidol

First published: June 2, 2023 DOI: 10.1016/j.jacl.2023.05.099
View
- Share
Articles
Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues
Sherratt SCR, Libby P, Budoff MJ, et al.
Journal:
Curr Atheroscler Rep

First published: December 29, 2022 DOI: 10.1007/s11883-022-01075-x
View
- Share
Articles
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan A, Glynn RJ, Fruchart JC, et al.
Journal:
NEJM

First published: November 5, 2022 DOI: 10.1056/NEJMoa2210645
View
- Share
Articles
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
Ridker PM, Rifai N, MacFadyen J, et al.
Journal:
Circulation

First published: June 28, 2022 DOI: 10.1161/CIRCULATIONAHA.122.059410
View
- Share
Articles
Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT
Gaba P, Bhatt DL, Mason RP, et al.
Journal:
J Clin Lipidol

First published: June 4, 2022 DOI: 10.1016/j.jacl.2022.05.067
View
- Share
Articles
The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl
Derington CG, Bress AP, Herrick JS, et al.
Journal:
Am J Prev Cardiol

First published: April 28, 2022 DOI: 10.1016/j.ajpc.2022.100345
View
- Share
Articles
Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)
Ballantyne CM, Banach M, Bays HE, et al.
Journal:
Am J Cardiol

First published: April 26, 2022 DOI: 10.1016/j.amjcard.2022.03.020
View
- Share
Articles
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins
Visser J, van Zwol W, Kuivenhoven JA
Journal:
Curr Atheroscler Rep

First published: February 2, 2022 DOI: 10.1007/s11883-022-00979-y
View
- Share
Articles
Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members
Lin PC, Chen CY, Wu C, et al.
Journal:
Biomedicines

First published: February 2, 2022 DOI: 10.3390/biomedicines10020367
View
- Share
Articles
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu L, Libby P
Journal:
Eur Heart J

First published: January 20, 2022 DOI: 10.1093/eurheartj/ehab841
View
- Share
Articles
Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update
Alsayed N, Almahmeed W, Alnouri F, et al.
Journal:
Atherosclerosis

First published: December 9, 2021 DOI: 10.1016/j.atherosclerosis.2021.11.022
View
- Share
Articles
National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High of Very-High ASCVD Risk
Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki
Journal:
J Clin Lipidol

First published: November 2, 2021 DOI: 10.1016/j.jacl.2019.10.014
View
- Share

1 2

Triglycerides Articles

Articles

Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association

Kirkpatrick CF, Sikand G, Petersen KS, et al.

Articles

Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues

Sherratt SCR, Libby P, Budoff MJ, et al.

Articles

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Das Pradhan A, Glynn RJ, Fruchart JC, et al.

Articles

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Ridker PM, Rifai N, MacFadyen J, et al.

Articles

Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT

Gaba P, Bhatt DL, Mason RP, et al.

Articles

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl

Derington CG, Bress AP, Herrick JS, et al.

Articles

Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)

Ballantyne CM, Banach M, Bays HE, et al.

Articles

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins

Visser J, van Zwol W, Kuivenhoven JA

Articles

Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members

Lin PC, Chen CY, Wu C, et al.

Articles

The dawn of a new era of targeted lipid-lowering therapies

Tokgözoğlu L, Libby P

Articles

Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update

Alsayed N, Almahmeed W, Alnouri F, et al.

Articles

National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High of Very-High ASCVD Risk

Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki

Articles

Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association

Kirkpatrick CF, Sikand G, Petersen KS, et al.

Share

Articles

Role of Omega-3 Fatty Acids in Cardiovascular Disease: the Debate Continues

Sherratt SCR, Libby P, Budoff MJ, et al.

Share

Articles

Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk

Das Pradhan A, Glynn RJ, Fruchart JC, et al.

Share

Articles

Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Ridker PM, Rifai N, MacFadyen J, et al.

Share

Articles

Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT

Gaba P, Bhatt DL, Mason RP, et al.

Share

Articles

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl

Derington CG, Bress AP, Herrick JS, et al.

Share

Articles

Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)

Ballantyne CM, Banach M, Bays HE, et al.

Share

Articles

Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins

Visser J, van Zwol W, Kuivenhoven JA

Share

Articles

Synergistic Effects of Inflammation and Atherogenic Dyslipidemia on Subclinical Carotid Atherosclerosis Assessed by Ultrasound in Patients with Familial Hypercholesterolemia and Their Family Members

Lin PC, Chen CY, Wu C, et al.

Share

Articles

The dawn of a new era of targeted lipid-lowering therapies

Tokgözoğlu L, Libby P

Share

Articles

Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update

Alsayed N, Almahmeed W, Alnouri F, et al.

Share

Articles

National Lipid Association Scientific Statement on the Use of Icosapent Ethyl in Statin-Treated Patients with Elevated Triglycerides and High of Very-High ASCVD Risk

Carl E. Orringer, Terry A. Jacobson, Kevin C. Maki

Share